Toucan Capital logo

Toucan Capital

North America, Maryland, United States, Bethesda

Description

Toucan Capital Fund II, L.P. is a $140 million venture capital fund focused on seed and early-stage life science and advanced technology

Investor Profile

Toucan Capital has made 8 investments, with 0 in the past 12 months and 38% as lead.

Stage Focus

  • Series D (25%)
  • Series C (25%)
  • Series B (13%)
  • Series Unknown (13%)
  • Series A (13%)
  • Post Ipo Equity (13%)

Country Focus

  • United States (100%)

Industry Focus

  • Advanced Materials
  • Energy
  • Manufacturing
  • Nanotechnology
  • Renewable Energy
  • Biotechnology
  • Medical
  • Health Care
  • Biopharma
  • Pharmaceutical
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Toucan Capital frequently co-invest with?

Next47
North America, California, United States, Palo Alto
Co-Investments: 2
VI
Asia, Hong Kong Island, Hong Kong, Hong Kong
Co-Investments: 1
Sevin Rosen Funds
North America, Texas, United States, Dallas
Co-Investments: 3
Johnson & Johnson Development Corporation
North America, New Jersey, United States, New Brunswick
Co-Investments: 1
BD
North America, California, United States, Palo Alto
Co-Investments: 1
Oxford Bioscience Partners
North America, Massachusetts, United States, Boston
Co-Investments: 1
CB Health Ventures
North America, Massachusetts, United States, Boston
Co-Investments: 1
Valley Ventures
North America, Arizona, United States, Phoenix
Co-Investments: 1
Guidant
North America, Indiana, United States, Indianapolis
Co-Investments: 1
Silicon Alley Venture Partners
North America, New York, United States, New York
Co-Investments: 4

What are some of recent deals done by Toucan Capital?

INmuneBIO

La Jolla, California, United States

INmune Bio is developing therapies that harness the patient’s immune system to treat cancer.

BiotechnologyCommercialIndustrialMedical
Post Ipo EquityJun 10, 2019
Amount Raised: $7,000,000
Reactive NanoTechnologies

Hunt Valley, Maryland, United States

Reactive NanoTechnologies develops and manufactures products to control the instantaneous release of heat energy.

Advanced MaterialsEnergyManufacturingNanotechnologyRenewable Energy
Series DMay 2, 2008
Amount Raised: $4,800,000
Q Therapeutics

Salt Lake City, Utah, United States

Q Therapeutics develops cell-based therapeutics which focuses on developing novel products to treat amyotrophic lateral sclerosis, etc.,

BiotechnologyHealth CareTherapeutics
Series UnknownFeb 15, 2008
Amount Raised: $15,000,000
Reactive NanoTechnologies

Hunt Valley, Maryland, United States

Reactive NanoTechnologies develops and manufactures products to control the instantaneous release of heat energy.

Advanced MaterialsEnergyManufacturingNanotechnologyRenewable Energy
Series CJan 7, 2008
Amount Raised: $6,350,000
Pepgen

Alameda, California, United States

Pepgen is a privately-held biopharmaceutical company that develops novel products for the treatment of autoimmune and viral disorders.

BiopharmaMedicalPharmaceutical
Series DAug 3, 2004
Amount Raised: $7,500,000
Intrapace

San Jose, California, United States

Intrapace develops a novel implantable system to treat obesity.

BiotechnologyHealth CareHealth Diagnostics
Series CJul 14, 2004
Amount Raised: $14,600,000
Reactive NanoTechnologies

Hunt Valley, Maryland, United States

Reactive NanoTechnologies develops and manufactures products to control the instantaneous release of heat energy.

Advanced MaterialsEnergyManufacturingNanotechnologyRenewable Energy
Series BMar 5, 2004
Amount Raised: $8,240,000
Reactive NanoTechnologies

Hunt Valley, Maryland, United States

Reactive NanoTechnologies develops and manufactures products to control the instantaneous release of heat energy.

Advanced MaterialsEnergyManufacturingNanotechnologyRenewable Energy
Series AJan 3, 2003
Amount Raised: $1,050,000